Real-world data of ocrelizumab effects on disability progression; A 2-year follow-up study

Creative Commons License

Baba C., Kaya E., Özçelik S., Özdoğar A. T., Sağıcı Ö., Daştan S., ...More

ECTRIMS 2022, Amsterdam, Netherlands, 26 - 28 October 2022, vol.28, no.821, pp.860

  • Publication Type: Conference Paper / Summary Text
  • Volume: 28
  • Doi Number: 10.1177/13524585221123682
  • City: Amsterdam
  • Country: Netherlands
  • Page Numbers: pp.860
  • Dokuz Eylül University Affiliated: Yes


Introduction: Ocrelizumab is an effective treatment in reduc-ing relapse rate and slowing disability progression in the short term.Aims:To  evaluate  disability  progression  in  people  with  multiple  sclerosis (pwMS) treated with ocrelizumab.Methods:  pwMS  candidates  for  ocrelizumab  treatment  were  enrolled in this prospective single-center observational study and followed up for two years. Disability was evaluated with Expanded Disability Status Scale (EDSS), Timed 25 Feet Walk (T25F) test, 9 Hole Peg Test (9HPT), Timed up and Go (TUG) test, and Twelve Item  MSWalking  Scale  (MSWS)  survey.  First  assessments  were  done before the ocrelizumab initiation and every six months after-ward.  Patients  with  secondary  progressive  and  primary  progres-sive  MS  were  analyzed  as  progressive  MS  (PMS).  A  change  of  %20   in   test   performance   time   was   considered   clinically   significant.Results:  107  PMS  patients  were  enrolled.  When  analyzed  sepa-rately,  there  was  no  significant  difference  between  baseline  and  two-year follow-up scores in total EDSS and functional subscores (p>0.05).  PMS  showed  significant  worsening  in  the  TUG  test  (p=0.043) in the first, T25FW (p=0.03) in the second, and MSWS-12 scores in the first (N:99, p:0,006) and the second (N:43 p:0.002) years of evaluation in comparison to baseline results. Of 53 PMS evaluated in the second year, 39 had not shown significant change on  9HPT  results,  two  had  improved  performance,  and  12  had  a  %20 increase in the test time compared to baseline. Overall 9HPT results  did  not  show  a  significant  change  in  two-year  follow-up  (p>0.05).Conclusions:  Although  ocrelizumab  does  not  show  favorable  results in the lower extremity functions in the progressive form, it could halt the disability accumulation in the upper extremity in the long term. Disclosure Cavid Baba: nothing to disclose Ergi Kaya: nothing to disclose Sinem Ozcelik: nothing to disclose Asiye Tuba Ozdogar: nothing to disclose Ozge Sagici: nothing to disclose Seda Dastan: nothing to disclose Serkan Ozakbas: nothing to disclose